Azacitidine and Chimerism in MDS or AML Patients After Allogeneic Stem Cell Transplant

Summary

Previous studies provide a rationale for administration of AZA after allo SCT for decreasing chimerism. The investigators hypothesize that azacitidine can be well tolerated after SCT and help decrease rate of decreasing donor chimerism and hence decrease relapse without increasing GVHD

Timeline

Start

2019-07-01

Primary completion

2028-02-20

Completion

2028-02-20

Drugs

Indications